Nevirapine prolonged release (PR) once-daily formulation available in the UK
Following the approval in Europe last year of a prolonged release (PR) formulation of nevirapine (called extended release/XR in the US), this 400 mg once-daily tablet is now available in the UK.
The lead in dose of 200 mg once daily (using the original formulation) is still required, with the same caution not to increase to the 400 mg daily dose if the patient shows rash at the end of these 14 days.
The daily price of nevirapine PR has been price matched to the price of the 200 mg formulation.
Boehringer press release: Viramune (nevirapine) prolonged-release once-daily formulation receives approval in the EU. (Septemebr 2011).